Ask to take part

Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.

Contact Information:

Lorna Smith +44 0203 437 6647
soprano-icrctsu@icr.ac.uk


Laura Moretti +44 0208 722 4153
soprano-icrctsu@icr.ac.uk


Study Location:

Find another location


Questions to ask
Skip to Main Content
English | Cymraeg
Be Part of Research - Trial Details - SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy
Back

SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy

Recruiting

Open to: FEMALE

Age: 18.0 - N/A

London Sutton London

Medical Conditions

Ovarian Neoplasms
Carcinoma, Ovarian Epithelial

This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.


SOPRANO is a multi-centre, randomised phase II trial which aims to assess the impact of Stereotactic radiotherapy (SBRT) and continuing treatment with a PARP inhibitor (PARPi) for patients with oligometastatic or oligoprogressive ovarian, fallopian tube and primary peritoneal carcinoma. SOPRANO will also establish the feasibility and acceptability of delivering SBRT in this setting.

Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.  

The recruitment start and end dates are as follows:

Jun 2024 Jun 2027

INTERVENTIONAL

Intervention Type : DRUG
Intervention Description : Niraparib used following SBRT treatment until disease progression

Intervention Arm Group : SBRT followed by Niraparib;

Intervention Type : RADIATION
Intervention Description : SBRT may be delivered using a specialist SBRT platform, such as CyberKnife or with a linear accelerator with SBRT capabilities.

Intervention Arm Group : SBRT alone;SBRT followed by Niraparib;



You can take part if:



You may not be able to take part if:


This is in the inclusion criteria above


Below are the locations for where you can take part in the trial. Please note that not all sites may be open.

  • The Royal Marsden NHS Foundation Trust
    London
    SW3 6JJ
  • The Royal Marsden NHS Foundation Trust
    Sutton
    Surrey
    SM2 5PT
  • University College London Hospitals
    London
    UK
    NW1 2PG

Lorna Smith +44 0203 437 6647
soprano-icrctsu@icr.ac.uk


Laura Moretti +44 0208 722 4153
soprano-icrctsu@icr.ac.uk



The study is sponsored by Institute of Cancer Research, United Kingdom and is in collaboration with Royal Marsden NHS Foundation Trust.



We'd like your feedback

Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.


Is this study information helpful?

What will you do next?
Read full details for Trial ID: NCT05990192
Last updated 16 October 2024

This page is to help you find out about a research study and if you may be able to take part

You can print or share the study information with your GP/healthcare provider or contact the research team directly.   

Back to the top